Exhibit 10.1


 


ICAGEN, INC.


SECURITIES PURCHASE AGREEMENT


 


This SECURITIES
PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of [__________], by and between
Icagen, Inc., a Delaware corporation (the “Company”), and the investors set forth on the signature pages
affixed hereto (each, an “Investor” and, collectively, the “Investors”).


 


WHEREAS, subject
to the terms and conditions set forth in this Agreement and pursuant to exemptions from registration under the Securities Act (as
defined below), the Company desires to issue and sell to each Investor, and each Investor, severally and not jointly, desires to
purchase from the Company, the Securities of the Company as, as more fully described in this Agreement;


  


WHEREAS, in
connection with the Investors’ purchase of the Securities, the Investors will be subject to certain restrictions on the transfer
of the Securities, all as more fully set forth in this Agreement.


 


NOW, THEREFORE,
in consideration of the mutual terms, conditions and other agreements set forth herein and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties hereto hereby
agree to the sale and purchase of the Units as set forth herein.


 


1. Definitions.


 


For purposes of this
Agreement, the terms set forth below shall have the corresponding meanings provided below.


 


“Affiliate”
shall mean, with respect to any specified Person (as defined below), (i) if such Person is an individual, the spouse, heirs, executors,
or legal representatives of such individual, or any trusts for the benefit of such individual or such individual’s spouse
and/or lineal descendants, or (ii) otherwise, another Person that directly, or indirectly through one or more intermediaries, controls,
is controlled by, or is under common control with, the Person specified. As used in this definition, “control” shall
mean the possession, directly or indirectly, of the sole and unilateral power to cause the direction of the management and policies
of a Person, whether through the ownership of voting securities or by contract or other written instrument.


 


“Business
Day” shall mean any day on which banks located in New York City are not required or authorized by law to remain closed.


 


“Closing” and “Closing
Date” as defined in Section 2.2(c) hereof.


 


“Common Stock”
means the common stock of the Company, par value $0.001 per
share, and any other class of securities into which such securities may hereafter be reclassified or changed.  


 


“Company Financial
Statements” as defined in Section 4.5(a) hereof.


 


“Company’s
Knowledge” means the actual knowledge of the Chief Executive Officer (as defined in Rule 405 under the Securities Act),
or the knowledge of any fact or matter which the Chief Executive Officer would reasonably be expected to become aware of in the
course of performing the duties and responsibilities.


 


“Company Permits”
as defined in Section 4.6 hereof.


 


“Exchange
Act” means the Securities Exchange Act of 1934, as amended.


 


“First Closing” and “First
Closing Date” as defined in Section 2.2(a) hereof.


 


“Intellectual Property Rights”
as defined in Section 4.13 hereof.


 






     


     


    

 


“Liens”
means any mortgage, lien, title claim, assignment, encumbrance, security interest, adverse claim, contract of sale, restriction
on use or transfer or other defect of title of any kind.


 


“Material
Adverse Effect” means a material adverse effect on (i) the assets, liabilities, results of operations, condition (financial
or otherwise), business, or prospects of the Company; (ii) the transactions contemplated hereby or in any of the Transaction Documents;
or (iii) the ability of the Company to perform its obligations under the Transaction Documents (as defined below).


 


“Note”
means the 15% Subordinated Promissory Note due February 28, 2023, issued by the Company to the Investor in the form of Exhibit
A attached hereto.


 


“Person”
shall mean an individual, entity, corporation, partnership, association, limited liability company, limited liability partnership,
joint-stock company, trust or unincorporated organization.


 


“Principal
Amount” means as to the Investor, the amount set forth below the Investor’s
signature block on the signature pages hereto next to the heading “Principal Amount,” in United States Dollars, which
shall equal the Investor’s Subscription Amount.


  


“Regulation
D” as defined in Section 3.7 hereof.


 


“Regulation
S” as defined in Section 5.1(5) hereof.


 


“Rule 144” means Rule
144 promulgated under the Securities Act (or a successor rule).


 


“SEC”
means the U.S. Securities and Exchange Commission.


 


“SEC Documents”
as defined in Section 4.5 hereof.


 


“Securities” mean the
Notes, Series C Preferred Stock Shares and Warrant.


 


“Securities
Act” means the Securities Act of 1933, as amended.


 


“Senior
Agent” as defined in Section 8.15 hereof.


 


“Senior
Indebtedness” as defined in Section 8.15 hereof.


 


“Series
C Preferred Stock” shall mean the Company’s shares of preferred stock designated as Series C Preferred Stock, having
the right, terms and preferences as set forth in the Certificate of Designation of the Company attached as Exhibit B hereto.


 


“Subsequent Closing”
and “Subsequent Closing Date” as defined in Section 2.2(b) hereof.


 


“Subsidiaries”
shall mean any corporation or other entity or organization, whether incorporated or unincorporated, in which the Company owns,
directly or indirectly, any equity or other ownership interest or otherwise controls through contract or otherwise.


 


“Transaction
Documents” shall mean this Agreement, the Note and the Warrant.


 


“Transfer”
shall mean any sale, transfer, assignment, conveyance, charge, pledge, mortgage, encumbrance, hypothecation, security interest
or other disposition, or to make or effect any of the above.


 


“Warrants”
means the warrants to purchase an aggregate of [__________] shares of Common Stock in the form attached as Exhibit C
to this Agreement.


 




    2


     


    

 


2. Sale and Purchase of Securities.


 


2.1. Purchase of
Securities by Investors. Subject to the terms and conditions of this Agreement, on each Closing Date (as hereinafter defined)
substantially concurrent with the execution and delivery of this Agreement by the applicable
parties hereto, the Company shall sell and issue to the Investors, and the Investors for
such amount set forth opposite each such Investor’s name in column (3) of the Schedule of Investors will purchase, severally
and not jointly, an aggregate of up to Five Hundred Thousand Dollars ($500,000) in Principal Amount of Notes. In consideration
for each Investor’s purchase of the Note, the Company shall issue to each such Investor a Warrant to purchase the number
of shares of Common Stock set forth opposite each such Investor’s name in column (4) of the Schedule of Investors (Warrants
to purchase 28,571 shares of Common Stock for each $100,000 Principal Amount of Notes) and the number of shares of Series C Preferred
Stock set forth opposite each such Investor’s name in column (5) of the Schedule of Investors (28,571 shares of Series C
Preferred Stock for each $100,000 Principal Amount of Notes”).


 


2.2. Closing.


 


(a) Closing. Subject to the
terms and conditions set forth in this Agreement, on each Closing Date, in addition to delivery
by each party of this Agreement duly executed by such party, upon the terms and subject to the conditions set forth herein, substantially
concurrent with the execution and delivery of this Agreement by the applicable parties hereto, the Purchasers on the Closing Date
set forth opposite each such Purchaser’s name in column (6) of the Schedule of Purchasers, will purchase, such Investor’s
Subscription Amount as set forth on the Schedule of Investors and signature page hereto executed by such Purchaser. At the Closing,
each such Investor shall deliver to the Company, via wire transfer to the account designated by the Company, immediately available
funds equal to such Investor’s Subscription Amount as set forth on the Schedule of Investors and the signature page hereto
executed by such Purchaser, and the Company shall deliver to such Investor its Note, in the Principal Amount set forth opposite
its name on the Schedule of Investors, the Warrant to purchase the number of shares of Common Stock set forth opposite its name
on the Schedule of Investors and the number of shares of Series C Preferred Stock set forth opposite its name on the Schedule of
Investors. Upon delivery of the foregoing, the Closing shall occur at the offices of Gracin & Marlow, LLP or
such other location as the parties shall mutually agree, and may by agreement be undertaken remotely by electronic exchange of
Closing documentation.


 


(b) There may be more
than one Closing after the initial Closing ; provided, however, that the final subsequent Closing shall take place
within the time periods determined by the Company. The date of any subsequent Closing is hereinafter referred to as a “Subsequent
Closing Date.” Notwithstanding the foregoing, the maximum aggregate Principal Amount of Notes following the First Closing
shall be $2,500,000. 


 


(c) Closing.
The initial Closing and any applicable subsequent Closings are each referred to in this Agreement as a “Closing.”
The initial Closing Date and any Subsequent Closing Dates are sometimes referred to herein as a “Closing Date.”
All Closings shall occur at the offices of Gracin & Marlow, LLP., counsel to the Company, at The Chrysler Building, 405 Lexington
Avenue, New York, New York 10174 or remotely via the exchange of documents and signatures.


  


3. Representations, Warranties and Acknowledgments of
the Investors.


 


Each Investor, severally
and not jointly, represents and warrants to the Company solely as to such Investor that:


 


3.1. Authorization.
The Purchaser is either an individual or an entity duly incorporated or formed, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership,
limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by this
Agreement and otherwise to carry out its obligations hereunder and thereunder. The execution, delivery and performance by
such Investor of this Agreement have been duly authorized and will constitute the valid and legally binding obligation of such
Investor, enforceable against such Investor in accordance with its respective terms, subject to bankruptcy, insolvency, fraudulent
transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’ rights
generally.


 






    3


     


    

 


3.2. Purchase
Entirely for Own Account. The Securities to be received by such Investor hereunder will be acquired for such Investor’s
own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the
Securities Act, and such Investor has no present intention of selling, granting any participation in, or otherwise distributing
the same in violation of the Securities Act, without prejudice, however, to such Investor’s right at all times to
sell or otherwise dispose of all or any part of such Securities in compliance with applicable federal and state securities laws.
Nothing contained herein shall be deemed a representation or warranty by such Investor to hold the Securities for any period of
time.


 


3.3. Investment
Experience. Such Investor acknowledges that the purchase of the Securities is a highly speculative investment and that it can
bear the economic risk and complete loss of its investment in the Securities and has such knowledge and experience in financial
or business matters such that it is capable of evaluating the merits and risks of the investment contemplated hereby.


 


3.4.  Disclosure
of Information. Such Investor has had an opportunity to receive all information related to the Company and the Securities requested
by it and to ask questions of and receive answers from the Company regarding the Company, its business and the terms and conditions
of the offering of the Securities. Neither such inquiries nor any other due diligence investigation conducted by such Investor
shall modify, amend or affect such Investor’s right to rely on the Company’s representations and warranties contained
in this Agreement. Such Investor acknowledges that it has received and reviewed the Company’s filings with the SEC and this
Agreement, the Note, the Warrant and the Series C Certificate of Designation.


 


3.5. Restricted
Securities. Such Investor understands that the Securities and the shares of Common Stock underlying the Warrant and into which
the Series C Preferred Stock may be converted, are characterized as “restricted securities” under the U.S. federal
securities laws since they are being acquired from the Company in a transaction not involving a public offering and that under
such laws and applicable regulations such securities may be resold without registration under the Securities Act only in certain
limited circumstances.


 


3.6. Legends.
It is understood that, except as provided below, certificates evidencing the Securities may bear the following or any similar legend:


 


(a) “The securities
represented hereby may not be transferred unless (i) such securities have been registered for sale pursuant to the Securities Act
of 1933, as amended; (ii) such securities may be sold pursuant to an available exemption from, or in a transaction not subject
to, the registration requirements of the Securities Act; or (iii) the Company has received an opinion of counsel reasonably satisfactory
to it that such transfer may lawfully be made without registration under the Securities Act of 1933 or qualification under applicable
state securities laws.”


 


(b)  If required
by the authorities of any state in connection with the issuance of sale of the Securities, the legend required by such state authority.


 


3.7. Accredited
Investor/ Bad Boy Acts. Such Investor, and if an entity, all equity holders of such Investor, is an accredited investor as
defined in Rule 501(a) of Regulation D, as amended, under the Securities Act (“Regulation D”). Such Investor
has not been the subject of any bad actor events under Rule 506 of Regulation D.


 


3.8. No General
Solicitation. Such Investor did not learn of the investment in the Securities as a result of any public advertising or general
solicitation.


  


3.9.
Brokers and Finders. Except for a fee payable to Taglich Brothers set forth on Schedule 3.9, no Investor will have, as a
result of the transactions contemplated by this Agreement, any valid right, interest or claim against or upon the Company, any
Subsidiary or any other Investor, for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding
entered into by or on behalf of such Investor.


 




    4


     


    

 


4. Representations and Warranties of the Company.


 


The Company represents,
warrants and covenants to the Investors that:


 


4.1. Organization;
Execution, Delivery and Performance.


 


(a) The Company
is a corporation or other entity duly organized, validly existing and in good standing under the laws of the jurisdiction in which
it is incorporated or organized, with full power and authority (corporate and other) to own, lease, use and operate its properties
and to carry on its business as and where now owned, leased, used, operated and conducted. The Company is duly qualified as a foreign
corporation to do business and is in good standing in every jurisdiction in which its ownership or use of property or the nature
of the business conducted by it makes such qualification necessary except where the failure to be so qualified or in good standing
would not have a Material Adverse Effect.


 


(b)(i) The Company has
all requisite corporate power and authority to enter into and perform the Transaction Documents and to consummate the transactions
contemplated hereby and thereby and to issue the Securities, in accordance with the terms hereof and thereof; (ii) the execution
and delivery of this Agreement by the Company and the consummation by the Company of the transactions contemplated hereby and thereby
(including without limitation, the issuance of the Securities) have been duly authorized by the Company’s Board of Directors
and no further consent or authorization of the Company, its Board of Directors, or its stockholders, is required; (iii) each of
the Transaction Documents has been duly executed and delivered by the Company by its authorized representative, and such authorized
representative is a true and official representative with authority to sign each such document and the other documents or certificates
executed in connection herewith and bind the Company accordingly; and (iv) each of the Transaction Documents constitutes, and upon
execution and delivery thereof by the Company will constitute, a legal, valid and binding obligation of the Company enforceable
against the Company in accordance with its terms, except to the extent limited by applicable bankruptcy, insolvency, reorganization,
moratorium or other laws of general application affecting enforcement of creditors’ rights and general principles of equity
that restrict the availability of equitable or legal remedies.


 


4.2. Securities
Duly Authorized. The Notes, Warrants and shares of Series C Preferred Stock to be issued to each such Investor pursuant to
this Agreement, when issued and delivered in accordance with the terms of this Agreement, will be duly and validly issued free
from all taxes or Liens with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights
of stockholders of the Company. The Notes, Warrants and shares of Series C Preferred Stock to be issued to each such Investor,
when issued in accordance with the terms of this Agreement, will be legal, valid and binding obligations of the Company enforceable
in accordance with their terms. The shares of Common Stock issuable upon exercise of the Warrants and upon conversion of the Series
C Preferred Stock in accordance with their respective terms will be duly and validly issued and fully paid and non-assessable.
Subject to the accuracy of the representations and warranties of the Investors to this Agreement, the offer and issuance by the
Company of the Securities is exempt from registration under the Securities Act.


  


4.3. No Conflicts.
The execution, delivery and performance of this Agreement, issuance of the Securities and the consummation by the Company of the
transactions contemplated hereby and thereby will not: (i) conflict with or result in a violation of any provision of the Certificate
of Incorporation or By-laws of the Company; or (ii) violate or conflict with, or result in a breach of any provision of, or constitute
a default (or an event which with notice or lapse of time or both could become a default) under, or give to others any rights of
termination, amendment, acceleration or cancellation of, any agreement, indenture, patent, patent license or instrument to which
the Company or any of its Subsidiaries is a party, except for possible violations, conflicts or defaults as would not, individually
or in the aggregate, have a Material Adverse Effect; or (iii) result in a violation of any law, rule, regulation, order, judgment
or decree (including federal and state securities laws and regulations and regulations of any self-regulatory organizations to
which the Company or its securities are subject) applicable to the Company or any of its Subsidiaries or by which any property
or asset of the Company or any of its Subsidiaries is bound or affected. Neither the Company nor any of its Subsidiaries is in
default (and no event has occurred which with notice or lapse of time or both could put the Company or any of its Subsidiaries
in default) under, and neither the Company nor any of its Subsidiaries has taken any action or failed to take any action that would
give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to
which the Company or any of its Subsidiaries is a party or by which any property or assets of the Company or any of its Subsidiaries
is bound or affected, or for possible defaults as would not, individually or in the aggregate, have a Material Adverse Effect.
The businesses of the Company and its Subsidiaries are not being conducted in violation of any law, rule ordinance or regulation
of any governmental entity, except for possible violations which would not, individually or in the aggregate, have a Material Adverse
Effect. Except as required under the Securities Act, the Exchange Act, and any applicable state securities laws, the Company is
not required to obtain any consent, authorization or order of, or make any filing or registration with, any court, governmental
agency, regulatory agency, self-regulatory organization or stock market or any third party in order for it to execute, deliver
or perform any of its obligations under this Agreement or to issue and sell the Securities in accordance with the terms hereof.
All consents, authorizations, orders, filings and registrations which the Company is required to obtain pursuant to the preceding
sentence have been obtained or effected on or prior to the date hereof.


 






    5


     


    

 


4.4. Capitalization.
As of August 1, 2019, the authorized capital stock of the Company consists of (i) 50,000,000 shares of Common Stock, of which 6,393,107
shares are outstanding, 10,000,000 shares of Preferred Stock, of which 400,000 are designated Series A Preferred Stock and no shares
are issued and outstanding, 3,000,000 shares are designated Series B Preferred Stock and no shares are issued and outstanding,
1,142,856 are designated as Series C Preferred Stock, of which 799,989 are issued and outstanding, 3,819,059 of the authorized
shares are reserved for the issuance of warrants, and 1,382,945 options have been issued to employees, consultants and directors
of

Icagen, Inc. In the Offering contemplated by this Agreement, warrants exercisable for up to 225,000 shares of Common Stock may
be issued to investors. The Company has reserved, and at all times will keep reserved, a sufficient number of shares for issuance
upon the conversion of the Notes and the exercise of the Warrants. Except as described in the SEC Documents, (i) there are no outstanding
options, warrants, scrip, rights to subscribe for, puts, calls, rights of first refusal, agreements, understandings, claims or
other commitments or rights of any character whatsoever relating to, or securities or rights convertible into or exchangeable for
any shares of capital stock of the Company or any of its Subsidiaries, or arrangements by which the Company or any of its Subsidiaries
is or may become bound to issue additional shares of capital stock of the Company or any of its Subsidiaries; (ii) there are no
agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale of any of its or
their securities under the Securities Act (except for the registration rights provisions contained herein and piggyback rights
of the Series A Preferred Stock) that will be triggered by the issuance of the Securities. All of such outstanding shares of capital
stock are, or upon issuance will be, duly authorized, validly issued, fully paid and nonassessable. No shares of capital stock
of the Company are subject to preemptive rights or any other similar rights of the stockholders of the Company or any Lien imposed
through the actions or failure to act of the Company.


 


4.5. SEC Information.


 


(a) The Company
has filed or furnished all registration statements, prospectuses, reports, schedules, forms, statements and other documents required
to be filed or furnished by it with the SEC pursuant to the requirements of the Securities Act or the Exchange Act (all of the
foregoing and all other documents filed with the SEC prior to the date hereof, being hereinafter referred to herein as the “SEC
Documents”). The SEC Documents have been made available to the Investors via the SEC’s EDGAR system. As of their
respective dates, the SEC Documents complied in all material respects with the requirements of the Exchange Act or the Securities
Act, as the case may be, and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none
of the SEC Documents, including any financial statements, schedules or exhibits included or incorporated by reference therein,
at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they
were made, not misleading. There are no outstanding any unresolved comments of the staff of the SEC. As of their respective dates,
the financial statements of the Company included in the SEC Documents (“Company Financial Statements”) complied
as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC
with respect thereto. The Company Financial Statements have been prepared in accordance with United States generally accepted accounting
principles (“GAAP”), consistently applied, during the periods involved (except (i) as may be otherwise indicated
in such financial statements or the notes thereto or (ii) in the case of unaudited interim statements, to the extent they may not
include footnotes or may be condensed or summary statements in accordance with GAAP and the applicable rules and regulations of
the SEC) and fairly present in all material respects the consolidated financial position of the Company and its consolidated Subsidiaries
as of the dates thereof and the consolidated results of their operations and cash flows for the periods then ended (subject, in
the case of unaudited statements, to normal year-end audit adjustments as permitted by GAAP and the applicable rules and regulations
of the SEC). Except as set forth in the Company Financial Statements, the Company has no liabilities, contingent or otherwise,
other than: (i) liabilities incurred in the ordinary course of business subsequent to March 31, 2019 (the fiscal period end of
the Company’s most recently-filed periodic report) and (ii) obligations under contracts and commitments incurred in the ordinary
course of business and not required under generally accepted accounting principles to be reflected in such financial statements,
which, individually or in the aggregate, are not material to the financial condition or operating results of the Company.


 


(b) The shares of
Common Stock are not currently traded on any market.


 






    6


     


    

 


4.6. Permits;
Compliance. The Company and each of its Subsidiaries is in possession of all franchises, grants, authorizations, licenses,
permits, easements, variances, exemptions, consents, certificates, approvals and orders necessary to own, lease and operate its
properties and to carry on its business as it is now being conducted (collectively, the “Company Permits”),
and there is no action pending or, to the knowledge of the Company, threatened regarding suspension or cancellation of any of the
Company Permits. Neither the Company nor any of its Subsidiaries is in conflict with, or in default or violation of, any of the
Company Permits, except for any such conflicts, defaults or violations which, individually or in the aggregate, would not reasonably
be expected to have a Material Adverse Effect. Since January 1, 2019, neither the Company nor any of its Subsidiaries has received
any notification with respect to possible conflicts, defaults or violations of applicable laws, except for notices relating to
possible conflicts, defaults or violations, which conflicts, defaults or violations would not have a Material Adverse Effect.


 


4.7. Litigation.
There is no action, suit, claim, proceeding, inquiry or investigation before or by any court, public board, government agency,
self-regulatory organization or body pending or, to the knowledge of the Company or any of its Subsidiaries, threatened against
or affecting the Company or any of its Subsidiaries, or their respective businesses, properties or assets or their officers or
directors in their capacity as such, that would have a Material Adverse Effect. The Company is unaware of any facts or circumstances
which might give rise to any of the foregoing. There has not been, and to the Company’s Knowledge, there is not pending or
contemplated, any investigation by the SEC involving the Company, any of its Subsidiaries or any current or former director or
executive officer of the Company or any of its Subsidiaries.


  


4.8. No Material Changes.


 


(a) Since March
31, 2019, except as set forth in the SEC Documents and additional operating expenses, there has not been:


 


(i) Any
material adverse change in the financial condition, operations or business of the Company from that shown on the Company Financial
Statements, or any material transaction or commitment effected or entered into by the Company outside of the ordinary course of
business;


 


(ii) Any
effect, change or circumstance which has had, or could reasonably be expected to have, a Material Adverse Effect; or


 


(iii) Any
incurrence of any material liability outside of the ordinary course of business.


 


4.9.  No General
Solicitation. Neither the Company nor any person participating on the Company’s behalf in the transactions contemplated
hereby has conducted any “general solicitation,” as such term is defined in Regulation D promulgated under the Securities
Act, with respect to any of the Securities being offered hereby.


 


4.10.  No Integrated
Offering. Neither the Company, nor any of its Affiliates, nor any person acting on its or their behalf, has directly or indirectly
made any offers or sales in any security or solicited any offers to buy any security under circumstances that would require registration
under the Securities Act of the issuance of the Securities to the Investors. The issuance of the Securities to the Investors will
not be integrated with any other issuance of the Company’s securities (past, current or future) for purposes of any stockholder
approval provisions applicable to the Company or its securities.


 


4.11.  No Brokers.
Except as set forth on Schedule 3.9, the Company has taken no action which would give rise to any claim by any person for brokerage
commissions, transaction fees or similar payments relating to this Agreement or the transactions contemplated hereby.


 






    7


     


    

 


4.12. Form
D; Blue Sky Laws. The Company agrees to file a Form D with respect to the Securities as required under Regulation D within
ten days after the First Closing. The Company shall, on or before the Closing Date, take such action as the Company shall reasonably
determine is necessary to qualify the Securities for sale to the Investors at the applicable Closing pursuant to this Agreement
under applicable securities or “blue sky” laws of the states of the United States (or to obtain an exemption from such
qualification).


 


4.13. Intellectual
Property Rights. The Company and its Subsidiaries own or possess adequate rights to use or licenses to use all trademarks,
trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, original works, inventions,
licenses, approvals, governmental authorizations, trade secrets and other intellectual property rights and all applications and
registrations therefor (“Intellectual Property Rights”) necessary to conduct their respective businesses as
now conducted and as presently proposed to be conducted. None of the Company’s or its Subsidiaries’ Intellectual Property
Rights have expired, terminated or been abandoned, or are expected to expire, terminate or be abandoned, within two years from
the date of this Agreement. The Company has no knowledge of any infringement by the Company or any of its Subsidiaries of Intellectual
Property Rights of others. Except as set forth in the SEC Documents, there is no claim, action or proceeding being made or brought,
or to the Company’s Knowledge, being threatened, against the Company or any of its Subsidiaries regarding their Intellectual
Property Rights. The Company is not aware of any facts or circumstances which might give rise to any of the foregoing infringements
or claims, actions or proceedings. The Company and each of its Subsidiaries have taken reasonable security measures to protect
the secrecy, confidentiality and value of all of their Intellectual Property Rights, except where failure to take such measures
would not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. 


 


4.14. Tax Status.
Except for occurrences that would not, either individually or in the aggregate, reasonably be expected to result in a Material
Adverse Effect, the Company and each of its Subsidiaries (i) has timely made or filed all foreign, federal and state income and
all other tax returns, reports and declarations required by any jurisdiction to which it is subject; (ii) has timely paid all taxes
and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports
and declarations, except those being contested in good faith; and (iii) has set aside on its books provision reasonably adequate
for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There
are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the
Company and its Subsidiaries know of no basis for any such claim. The Company is not operated in such a manner as to qualify as
a passive foreign investment company, as defined in Section 1297 of the U.S. Internal Revenue Code of 1986, as amended.


 


4.15. Shell
Company Status. The Company was never a “shell issuer”, as defined in Rule 144(i)(1).


 


4.16. Investment
Company Act Status. The Company and its subsidiaries are not, and after giving effect to the offering and sale of the Units
will not be, required to register as an “investment company” as such term is defined in the Investment Company Act
of 1940, as amended.


 


5. Transfer Restrictions.


 


5.1. Transfer
or Resale. Each Investor understands that:


 


The sale or resale of
all or any portion of the Securities has not been and is not being registered under the Securities Act or any applicable state
securities laws, and all or any portion of the Securities may not be transferred unless:


 


(1)  the Securities
are sold pursuant to an effective registration statement under the Securities Act;


 


(2)  the Investor
shall have delivered to the Company, at the cost of the Company, a customary opinion of counsel that shall be in form, substance
and scope reasonably acceptable to the Company, to the effect that the Securities to be sold or transferred may be sold or transferred
pursuant to an exemption from such registration;


 






    8


     


    

 


(3)  the Securities
are sold or transferred to an “affiliate” (as defined in Rule 144) of the Investor who agrees to sell or otherwise
transfer the Securities only in accordance with this Section 5.1 and who is an Accredited Investor;


 


(4)  the Securities
are sold pursuant to Rule 144; or


 


(5)  the Securities
are sold pursuant to Regulation S under the Securities Act (or a successor rule) (“Regulation S”);


 


and, in each case, the Investor shall have
delivered to the Company, at the cost of the Company, a customary opinion of counsel, in form, substance and scope reasonably acceptable
to the Company. Notwithstanding the foregoing or anything else contained herein to the contrary, the Securities may be pledged
as collateral in connection with a bona fide margin account or other lending arrangement. 


 


5.2  Transfer
Agent Instructions. If an Investor provides the Company with a customary opinion of counsel, that shall be in form, substance
and scope reasonably acceptable to the Company, to the effect that a public sale or transfer of such Securities may be made without
registration under the Securities Act and such sale or transfer is effected, the Company shall permit the transfer and promptly
instruct its transfer agent to issue one or more certificates, free from restrictive legend, in such name and in such denominations
as specified by such Investor. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable
harm to the Investors, by vitiating the intent and purpose of the transactions contemplated hereby. Accordingly, the Company acknowledges
that the remedy at law for a breach of its obligations under this Section 5.2 may be inadequate and agrees, in the event of a breach
or threatened breach by the Company of the provisions of this Section, that the Investors shall be entitled, in addition to all
other available remedies, to an injunction restraining any breach and requiring immediate transfer, without the necessity of showing
economic loss and without any bond or other security being required.


 


6. Conditions to Closing of the
Investors.


 


The obligation of each
Investor hereunder to purchase the Securities at the Closing is subject to the satisfaction, at or before the Closing Date, of
each of the following conditions, provided that these conditions are for each Investor’s sole benefit and may be waived by
such Investor at any time in its sole discretion by providing the Company with prior written notice thereof:


 


6.1. Representations,
Warranties and Covenants. The representations and warranties of the Company shall be true and correct in all material respects
as of the date when made and as of the Closing Date as though originally made at that time (except for representations and warranties
that speak as of a specific date, which shall be true and correct in all material respects as of such date) and the Company shall
have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required to be performed,
satisfied or complied with by the Company at or prior to the Closing Date.


 


6.2. Consents.
The Company shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary for the sale
of the Securities.


 


6.3. Delivery by
Company. The Company shall have duly executed and delivered to each Investor each of the Note, Warrant and shall have made
an entry in its books and records regarding the Series C Preferred Stock to be issued.


 


6.4. No Material
Adverse Effect. Since the date of first execution of this Agreement, no event or series of events shall have occurred that
reasonably would have or result in a Material Adverse Effect.


 


6.5. No Prohibition.
No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed
by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions contemplated
by the Transaction Documents.


 






    9


     


    

 


6.6. Other Documents.
The Company shall have delivered to such Investor such other documents, instruments or certificates relating to the transactions
contemplated by this Agreement as such Investor or its counsel may reasonably request.


 


7.  Conditions to Closing of the Company.


 


The obligations of
the Company to effect the transactions contemplated by this Agreement with each Investor are subject to the fulfillment at or prior
to each Closing Date of the conditions listed below. 


 


7.1. Representations
and Warranties. The representations and warranties made by such Investor in Section 3 shall be true and correct in all material
respects at the time of Closing as if made on and as of such date.


 


7.2. Corporate Proceedings.
All corporate and other proceedings required to be undertaken by such Investor in connection with the transactions contemplated
hereby shall have occurred and all documents and instruments incident to such proceedings shall be reasonably satisfactory in substance
and form to the Company.


 


7.3. Delivery
by the Investor. The Investor shall have duly executed and delivered to the Company (a) each of the other Transaction Documents
to be signed by the Investor and (b) a Purchaser Questionnaire and a Purchaser Information Request.


 


8. Miscellaneous.


 


8.1. Notices.
All notices, requests, demands and other communications provided in connection with this Agreement shall be in writing and shall
be deemed to have been duly given at the time when hand delivered, delivered by express courier, or sent by facsimile (with receipt
confirmed by the sender’s transmitting device) in accordance with the contact information provided below or such other contact
information as the parties may have duly provided by notice.


 


	
        The Company:

         

        Icagen, Inc.

        4222 Emperor Blvd., Suite 350

        Durham, North Carolina 27703

        Telephone: (919) 941-5206

        Facsimile: (302) 347-1326

        Attention: Mark Korb

                          Chief Financial Officer
	 	
        With a copy to:

         

        Gracin& Marlow, LLP

        The Chrysler Building

        405 Lexington Avenue, 26th Floor

        New York, New York 10174

        Attention: Leslie Marlow, Esq.

        Telephone: (212) 907-6457

        Facsimile: (212) 208-4657




 


The Investors:


 


As per the contact information provided on the signature pages hereof.



 


8.2. Survival of
Representations and Warranties. Each party hereto covenants and agrees that the representations and warranties of such party
contained in this Agreement shall survive the Closing. Each Investor shall be responsible only for its own representations, warranties,
agreements and covenants hereunder.


 


8.3. Indemnification.


 


(a)  The Company
agrees to indemnify and hold harmless each Investor and its Affiliates and their respective directors, officers, employees and
agents from and against any and all losses, claims, damages, liabilities and expenses (including without limitation reasonable
attorney fees and disbursements and other expenses incurred in connection with investigating, preparing or defending any action,
claim or proceeding, pending or threatened and the costs of enforcement thereof) (collectively, “Losses”) to
which such Person may become subject as a result of any breach of representation, warranty, covenant or agreement made by or to
be performed on the part of the Company under the Transaction Documents, and will reimburse any such Person for all such amounts
as they are incurred by such Person. 


 






    10


     


    

 


(b)  Promptly after
receipt by any Investor (the “Indemnified Person”) of notice of any demand, claim or circumstances which would
or might give rise to a claim or the commencement of any action, proceeding or investigation in respect of which indemnity may
be sought pursuant to this Section 8.3, such Indemnified Person shall promptly notify the Company in writing and the Company shall
assume the defense thereof, including the employment of counsel reasonably satisfactory to such Indemnified Person, and shall assume
the payment of all fees and expenses; provided, however, that the failure of any Indemnified Person so to notify
the Company shall not relieve the Company of its obligations hereunder except to the extent that the Company is materially prejudiced
by such failure to notify. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the
fees and expenses of such counsel shall be at the expense of such Indemnified Person unless: (i) the Company and the Indemnified
Person shall have mutually agreed to the retention of such counsel; or (ii) in the reasonable judgment of counsel to such Indemnified
Person representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests
between them. The Company shall not be liable for any settlement of any proceeding effected without its written consent, which
consent shall not be unreasonably withheld, but if settled with such consent, or if there be a final judgment for the plaintiff,
the Company shall indemnify and hold harmless such Indemnified Person from and against any loss or liability (to the extent stated
above) by reason of such settlement or judgment. Without the prior written consent of the Indemnified Person, which consent shall
not be unreasonably withheld, the Company shall not affect any settlement of any pending or threatened proceeding in respect of
which any Indemnified Person is or could have been a party and indemnity could have been sought hereunder by such Indemnified Party,
unless such settlement includes an unconditional release of such Indemnified Person from all liability arising out of such proceeding.


 


8.4. Entire Agreement.
This Agreement, the Notes and the Warrants contain the entire agreement between the parties hereto in respect of the subject matter
contained herein and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject
matter contained herein.


 


8.5. Third Party
Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and
assigns only. Notwithstanding any of the foregoing to the contrary, the Senior Agent is a third-party beneficiary of the subordination
provisions contained in Section 8.15 below and shall be entitled to enforce such provisions as though it were a party hereto.


 


8.6. Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and assigns.
Neither the Company nor any Investor shall assign this Agreement or any rights or obligations hereunder without the prior written
consent of the other.


 


8.7. Use of Proceeds.
The proceeds derived from the sale of the Securities shall be used by the Company for its general working capital needs.


 


8.8. Binding
Effect; Benefits. This Agreement and all the provisions hereof shall be binding upon and inure to the benefit of the parties
hereto and their respective successors and permitted assigns; except as set forth in Section 8.5 above, nothing in this Agreement,
expressed or implied, is intended to confer on any persons other than the parties hereto or their respective successors and permitted
assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement.


 


8.9. Amendment;
Waivers. All modifications, amendments or waivers to this Agreement shall require the written consent of each of (i) the Company
and (ii) the Investors owning a majority in principal amount of the Notes.


 


8.10. Applicable
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York without giving
effect to the conflict of law provisions thereof, and the parties hereto.


 




    11


     


    

 


8.11.
Arbitration. Each Investor and the Company agree that they shall resolve all disputes, controversies and differences which
may arise between them, out of or in relation to or in connection with this Agreement, after discussion in good faith attempting
to reach an amicable solution. Provided that such disputes, controversies and differences remain unsettled after discussion between
the parties, both parties agree that those unsettled matter(s) shall be finally settled by arbitration in New York, New York in
accordance with the latest Rules of the American Arbitration Association. Such arbitration shall be conducted by three arbitrators
appointed as follows: each party will appoint one arbitrator and the appointed arbitrators shall appoint a third arbitrator. If
within thirty (30) days after confirmation of the last appointed arbitrator, such arbitrators have failed to agree upon a chairman,
then the chairman will be appointed by the American Arbitration Association. The decision of the tribunal shall be final and may
not be appealed. The arbitral tribunal may, in its discretion award fees and costs as part of its award. Judgment on the arbitral
award may be entered by any court of competent jurisdiction, including any court that has jurisdiction over either party or any
of their assets. At the request of any party, the arbitration proceeding shall be conducted in the utmost secrecy subject to a
requirement of law to disclose. In such case, all documents, testimony and records shall be received, heard and maintained by the
arbitrators in secrecy, available for inspection only by any party and by their attorneys and experts who shall agree, in advance
and in writing, to receive all such information in secrecy.


 


8.12. Further
Assurances. Each party hereto shall do and perform or cause to be done and performed all such further acts and shall execute
and deliver all such other agreements, certificates, instruments and documents as any other party hereto reasonably may request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.


 


8.13. Counterparts.
This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which
taken together shall constitute one and the same instrument. This Agreement may also be executed via facsimile, which shall be
deemed an original.


 


8.14. Independent
Nature of Investors. The obligations of each Investor under this Agreement or other transaction document are several and not
joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance of the obligations
of any other Investor under this Agreement or any other transaction document. Each Investor shall be responsible only for its own
representations, warranties, agreements and covenants hereunder. The decision of each Investor to purchase Securities pursuant
to this Agreement has been made by such Investor independently of any other Investor and independently of any information, materials,
statements or opinions as to the business, affairs, operations, assets, properties, liabilities, results of operations, condition
(financial or otherwise) or prospects of the Company which may have been made or given by any other Investor or by any agent or
employee of any other Investor, and no Investor or any of its agents or employees shall have any liability to any other Investor
(or any other person) relating to or arising from any such information, materials, statements or opinions. Nothing contained herein
or in any other transaction document, and no action taken by any Investor pursuant hereto or thereto, shall be deemed to constitute
the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors
are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by this Agreement.
Except as otherwise provided in this Agreement or any other transaction document, each Investor shall be entitled to independently
protect and enforce its rights arising out of this Agreement or out of the other transaction documents, and it shall not be necessary
for any other Investor to be joined as an additional party in any proceeding for such purpose. Each Investor has been represented
by its own separate legal counsel in connection with the transactions contemplated hereby.


 


8.15. Subordination.
Notwithstanding anything to the contrary set forth in this Agreement, the Company, for itself, its successors and assigns, covenants
and agrees, and each Investor by its acceptance of its Note likewise covenants and agrees, that the payment of principal and interest
on, and all other amounts due with respect to, its Note is hereby wholly subordinated, junior and subject in right of payment,
to the extent and in the manner set forth in Section 1 of its Note, to prior payment in full of all Senior Indebtedness (as
defined below) of the Company now or hereafter incurred. The provisions of this Section 8.15 shall constitute a continuing
offer to all persons who, in reliance upon such provisions, become holders of, or continue to hold, Senior Indebtedness. As used
in this Agreement, “Senior Indebtedness” means all present and future indebtedness of the Company pursuant
to (i) that certain Credit and Guaranty dated as of August 31, 2018, among the Company, certain subsidiaries of the Company party
from time to time thereto as subsidiary guarantors, the lenders from time to time party thereto and Perceptive Credit Holdings
II, LP, as the administrative agent thereunder (the “Senior Agent”) and (ii) that certain Credit and Guaranty
Agreement dated as of August 31, 2018, among Icagen-T, Inc., as borrower, the Company and certain subsidiaries of the Company
party thereto from time to time as guarantors, the lenders from time to time party thereto and the Senior Agent as administrative
agent thereunder.


 


[Signature Page to Follow]


 




    12


     


    

 


IN WITNESS WHEREOF,
the undersigned Investors and the Company have caused this Securities Purchase Agreement to be duly executed as of the date first
above written.


 


	 	ICAGEN, INC.
	 	 
	 	By: 	 
	 	Name: 	Richard Cunningham
	 	Title:	President and Chief Executive Officer


 


 [REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK


SIGNATURE PAGE FOR PURCHASER FOLLOWS]


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


[INVESTOR
SIGNATURE PAGES TO ICAGEN, INC. SECURITIES PURCHASE AGREEMENT]


 






    13


     


    

 


The undersigned, desiring to: (i)
enter into this Securities Purchase Agreement dated as of  [__________] (the “Agreement”), with the
undersigned, Icagen, Inc., a Delaware corporation (the “Company”), in or substantially in the form
furnished to the undersigned and (ii) purchase the Securities as set forth opposite the undersigned’s name on the
Schedule of Investors annexed to this Agreement, hereby agrees to purchase such Securities from the Company as of the Closing
and further agrees to join the Agreement as a party thereto, with all the rights and privileges appertaining thereto, and to
be bound in all respects by the terms and conditions thereof. The undersigned specifically acknowledges having read
the representations in the Agreement section entitled “Representations, Warranties and Acknowledgments of the
Investors,” and hereby represents that the statements contained therein are complete and accurate with respect to the
undersigned as an Investor.


 


	All Investors:
    	 	Name
    of Investor:
	 	 	 	 
	Address:	 	If
    an entity: 
	 	 	 	 
	Telephone No.:	 	Print
    Name of Entity:
	 	 	 	 
	Facsimile No.:	 	     	 
	 	 	By:	 
	Email Address:	 	Name:	 
	 	 	Title:	 
	 	 	 	 
	 	 	If
    an individual:
	 	 	 	 
	 	 	Print
    Name:
	 	 	 	 
	 	 	Signature: 	 
	 	 	 	 
	 	 	If
    joint individuals: 
	 	 	 	 
	 	 	Print Name:   	 
	 	 	 	 
	 	 	Signature: 	 
	 	 	 	 
	Closing Subscription Amount: $____________		 	 




 




    14


     


    

 


SCHEDULE OF INVESTORS


 


	 	(1)		 	 	(2)			 	(3)		 	 	(4)		 	 	(5)		 	 	(6)	 
	 	Investor	 	 	 	Principal Amount of
 Notes
	 	 	 	Subscription Amount	 	 	 	Shares of Common Stock Underlying Warrant  	 	 	 	Shares of Series C Preferred Stock	 	 	 	
 Closing Date
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 



 




    15


     


    

 


Annex
2


 


CONFIDENTIAL PURCHASER QUESTIONNAIRE


 


THIS QUESTIONNAIRE MUST BE ANSWERED FULLY
AND RETURNED ALONG WITH YOUR COMPLETED SUBSCRIPTION AGREEMENT IN CONNECTION WITH YOUR PROSPECTIVE PURCHASE OF UNITS FROM ICAGEN,
INC. (THE “COMPANY”).


 


THE INFORMATION SUPPLIED IN THIS QUESTIONNAIRE
WILL BE HELD IN STRICT CONFIDENCE. NO INFORMATION WILL BE DISCLOSED EXCEPT TO THE EXTENT THAT SUCH DISCLOSURE IS REQUIRED BY LAW
OR REGULATION, OTHERWISE DEMANDED BY PROPER LEGAL PROCESS OR IN LITIGATION INVOLVING THE COMPANY AND ITS CONTROLLING PERSONS.


 


Capitalized terms used herein without definition
shall have the respective meanings given such terms as set forth in the Subscription Agreement between Icagen, Inc. and the subscriber
signatory thereto (the “Subscription Agreement”).


 


(1) The undersigned
represents and warrants that he, she or it comes within at least one category marked below, and that for any category marked, he,
she or it has truthfully set forth, where applicable, the factual basis or reason the undersigned comes within that category. The
undersigned agrees to furnish any additional information which the Company deems necessary in order to verify the answers set forth
below.


 


	Category A __	The undersigned is an individual (not a partnership, corporation, etc.) whose individual net worth, or joint net worth with his or her spouse, presently exceeds $1,000,000.


 


Explanation. In calculating net
worth you may include equity in personal property and may include real estate, provided, however, you cannot include your principal
residence), cash, short-term investments, stock and securities. Equity in personal property and real estate should be based on
the fair market value of such property less debt secured by such property.


 


	Category B __	The undersigned is an individual (not a partnership, corporation, etc.) who had an income in excess of $200,000 in each of the two most recent years, or joint income with his or her spouse in excess of $300,000 in each of those years (in each case including foreign income, tax exempt income and full amount of capital gains and losses but excluding any income of other family members and any unrealized capital appreciation) and has a reasonable expectation of reaching the same income level in the current year.


 


	Category C __	The undersigned is a director or executive officer of the Company which is issuing and selling the Securities.


 


	Category D __	The undersigned is a bank, as defined in Section 3(a)(2) of the Securities Act of 1933, as amended (the “Act”); a savings and loan association or other institution as defined in Section 3(a)(5)(A) of the Act, whether acting in its individual or fiduciary capacity; any insurance company as defined in Section 2(13) of the Act; any investment company registered under the Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of that Act; any Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958; any plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has total assets in excess of $5,000,000; any employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974 if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such act, which is either a bank, savings and loan association, insurance company, or registered investment advisor, or if the employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made solely by persons that are accredited investors. (describe entity)
	 	 
	 	 


  






    Annex 2 - 1


     


    

 


	Category E __	The undersigned is a private business development company as defined in section 202(a) (22) of the Investment Advisors Act of 1940. (describe entity)
	 	 
	 	 


 


	Category F __	The undersigned is either a corporation, partnership, Massachusetts business trust, or non-profit organization within the meaning of Section 501(c)(3) of the Internal Revenue Code, in each case not formed for the specific purpose of acquiring the Securities and with total assets in excess of $5,000,000. (describe entity)
	 	 
	 	 


 


	Category G __	The undersigned is a trust with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Securities, where the purchase is directed by a “sophisticated investor” as defined in Regulation 506(b)(2)(ii) under the Act.
	 	 
	 	 


 


	Category H __	The undersigned is an entity (other than a trust) in which all of the equity owners are “accredited investors” within one or more of the above categories. If relying upon this Category alone, each equity owner must complete a separate copy of this Purchaser Questionnaire. (describe entity)
	 	 
	 	 


 


The undersigned agrees that the
undersigned will notify the Company at any time on or prior to the applicable closing in the event that the representations and
warranties in this Purchaser Questionnaire shall cease to be true, accurate and complete.


 


(2) Suitability (please answer each
question)


 


	 	(a)	For an individual, please describe your current employment, including the company by which you are employed and its principal business:
	 	 	 
	 	 	 
	 	 	 


 






    Annex 2 - 2


     


    

 


	 	(b)	For an individual, please describe any college or graduate degrees held by you:
	 	 	 
	 	 	 


 


	 	(c)	For all subscribers, please list types of prior investments:
	 	 	 
	 	 	 


  


	 	(d)	For all subscribers, please state whether you have you participated in other private placements before:


 


Yes ☐                              No
☐


 


	 	(e)	If your answer to question (d) above was “YES”, please indicate frequency of such prior participation in private placements of:


 


	 	 	Public

Companies	 	Private

Companies
	 	Frequently	 	 	 
	 	Occasionally	 	 	 
	 	Never	 	 	 


 


	 	(f)	For individuals, do you expect your current level of income to significantly decrease in the foreseeable future?


 


Yes ☐                              No
☐


 


	 	(g)	For trust, corporate, partnership and other institutional subscribers, do you expect your total assets to significantly decrease in the foreseeable future?


 


Yes ☐                              No
☐


 


	 	(h)	For all subscribers, do you have any other investments or contingent liabilities which you reasonably anticipate could cause you to need sudden cash requirements in excess of cash readily available to you?


 


Yes ☐                              No
☐


 


	 	(i)	For all subscribers, are you familiar with the risk aspects and the non-liquidity of investments such as the Securities for which you seek to purchase?


 


Yes ☐                              No
☐


 


[SIGNATURE
PAGE TO FOLLOW]


 




    Annex 2 - 3


     


    

 


The undersigned has been informed of the
significance to the Company of the foregoing representations and answers contained in this Confidential Purchaser Questionnaire
and such representations and answers have been provided with the understanding that the Company will rely on them.


 


		 	Individual
	 	 	 	 
	Date:	 	 	 	 	 
	 	 	Name of Individual
	 	 	(Please type or print)
	 	 	 	 
	 	 	 	 
	 	 	Signature of Individual
	 	 	 	 
	 	 	 	 
	 	 	Name of Joint Owner 
	 	 	(Please type or print)
	 	 	 	 
	 	 	 	 
	 	 	Signature (Joint Owner)
	 	 	 	 
	 	 	Partnership, Corporation or
	 	 	Other Entity
	 	 	 	 
	Date:	 	 	 	 	 
	 	 	Print or Type Entity Name
	 	 	 	 
	 	 	By:	                      
	 	 	Name:	 
	 	 	Title: 	 
	 	 	  	 
	 	 	Signature
	 	 	 	 
		 	Title:	 
	 	 	 	 
	 	 	 	 
	 	 	Signature (other authorized signatory)




 


 


Annex
2 - 4